Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2018 - 2026)

Lineage Cell Therapeutics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 0.82% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at $35.7 million (up 905.5% YoY), while the FY2025 annual figure was $35.7 million, up 1778.9% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$2.3 million, down from -$1.3 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $26.6 million in Q3 2025, with the low at -$2.3 million in Q1 2026.
• The 3-year median for Gains from Investment Securities is -$1.7 million (2024), against an average of $5.2 million.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities surged 40.55% in 2025, then decreased 0.82% in 2026.
• Lineage Cell Therapeutics' Gains from Investment Securities stood at -$2.1 million in 2024, then soared by 40.55% to -$1.3 million in 2025, then slumped by 83.72% to -$2.3 million in 2026.
• Business Quant data shows LCTX's Gains from Investment Securities at -$2.3 million in Q1 2026, -$1.3 million in Q4 2025, and $26.6 million in Q3 2025.